Detalhe da pesquisa
1.
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.
Breast Cancer Res Treat
; 186(1): 157-165, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150547
2.
Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test.
J Surg Oncol
; 122(4): 611-618, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497318
3.
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Breast Cancer Res Treat
; 177(3): 611-618, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31302854
4.
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Breast Cancer Res Treat
; 173(1): 123-133, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30242578
5.
Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in Brazil.
JCO Glob Oncol
; 7: 1003-1011, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34181482
6.
Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America.
JCO Glob Oncol
; 7: 1364-1373, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34506221
7.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
J Clin Oncol
; 38(7): 725-733, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31809240
8.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
NPJ Breast Cancer
; 5: 41, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728408